Study of a new drug for advanced solid tumors that haven't responded to treatment
Part of Cancer clinical trials.
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have a type of advanced solid tumor that has spread or come back, and that did not respond to at least two previous treatments.
- You must be generally able to do daily activities (ECOG score 0 or 1, meaning you are up and about).
- You must be at least 4 weeks past any chemotherapy, radiation, or surgery, and at least 6 weeks past certain stronger chemotherapy drugs (mitomycin or nitrosoureas).
- Your major organs (like heart, liver, kidneys) must be working well enough, and you cannot have uncontrolled heart problems, active serious infections, autoimmune diseases, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This early-stage trial tests a new medicine called NCP-IL-22BP mRNA, given as an injection, to see if it is safe and well-tolerated in patients with advanced cancers that have not responded to standard treatments. The medicine is designed to boost your immune system to fight cancer cells.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This early-stage trial tests a new drug that combines a peptide with genetic material (siRNA) designed to help your immune system fight advanced cancers that haven't responded to standard treatments. Researchers want to see if it's safe and whether it can shrink tumors.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
This trial tests a new experimental drug called LNF1901 for people with advanced cancers that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Refractory Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.